A patient with bipolar II disorder who was started on aripiprazole (Abilify) developed significant akathisia, was switched to lurasidone (Latuda) but the akathisia persists; how should this be managed?

Management of Persistent Akathisia in Bipolar II Disorder After Switching from Aripiprazole to Lurasidone

For this patient with persistent akathisia despite switching from aripiprazole to lurasidone, immediately add propranolol (or another lipophilic beta-blocker) as first-line pharmacological treatment, and if this fails, add a benzodiazepine for additional symptomatic relief. 1, 2

Understanding the Clinical Situation

This case represents a challenging scenario where akathisia has persisted despite switching antipsychotics. Both aripiprazole and lurasidone can cause akathisia even at low doses, with aripiprazole being particularly notorious for this side effect despite being a second-generation antipsychotic. 3 The persistence of akathisia after switching suggests either:

• Residual akathisia from aripiprazole that hasn't fully resolved
• New akathisia induced by lurasidone (which can occur even though lurasidone generally has lower extrapyramidal side effect rates)
• Possible tardive or chronic akathisia developing from the initial exposure 4

Immediate Management Algorithm

Step 1: Pharmacological Treatment of Akathisia

Add propranolol as first-line therapy, starting at 20-40 mg daily and titrating up to 80-120 mg daily in divided doses as needed. 1, 2 Propranolol and other lipophilic beta-blockers are the most consistently effective treatments for acute akathisia based on available evidence. 2

Step 2: If Beta-Blockers Fail or Are Contraindicated

Add a benzodiazepine (such as lorazepam 0.5-2 mg twice daily or clonazepam 0.5-1 mg twice daily) for additional relief, particularly if subjective distress persists. 1, 2 The APA guidelines specifically suggest benzodiazepines as an option for antipsychotic-associated akathisia. 1

Step 3: Consider Additional Options

If both beta-blockers and benzodiazepines are unsuccessful:

• Low-dose mirtazapine (7.5-15 mg at bedtime) has good evidence for akathisia management 4
• Gabapentin or pregabalin (voltage-gated calcium channel blockers) may provide relief 4
• Amantadine or clonidine can be tried as alternative agents 2

Antipsychotic Management Considerations

Option A: Reduce Lurasidone Dose

Consider lowering the lurasidone dose if the patient's bipolar symptoms are adequately controlled, as this may reduce akathisia severity while maintaining therapeutic benefit. 1

Option B: Switch to a Different Antipsychotic

If akathisia remains intolerable despite pharmacological management, switch to an antipsychotic with lower akathisia risk for bipolar II disorder:

• Quetiapine (generally lower extrapyramidal side effect profile) 5
• Lamotrigine as a mood stabilizer (no akathisia risk, though primarily effective for bipolar depression) 5, 6
• Cariprazine (newer option with efficacy in bipolar disorder, though akathisia can still occur) 7, 5

Important caveat: Even antipsychotics with minimal extrapyramidal side effects like quetiapine can occasionally cause akathisia, though this is rare. 4

Critical Clinical Pitfalls

Timing Considerations

Akathisia from aripiprazole may take 2-4 weeks to fully resolve after discontinuation, as demonstrated in case reports where symptoms persisted despite management measures and only resolved after 4 weeks. 8, 3 Don't assume immediate resolution after switching.

Drug Interactions

Be vigilant about drug-drug interactions that can precipitate or worsen akathisia. Certain antibiotics (particularly fluoroquinolones like ciprofloxacin) and antifungals can interact with antipsychotics to cause or exacerbate akathisia. 8

Withdrawal Akathisia

If lurasidone was started at a high dose or increased rapidly, consider that this could represent withdrawal akathisia from the abrupt aripiprazole discontinuation rather than lurasidone-induced akathisia. 9 This distinction matters because withdrawal akathisia may require slower tapering strategies in the future.

Monitoring and Follow-Up

• Use the Barnes Akathisia Rating Scale to objectively quantify severity and track response to treatment 8
• Monitor for both subjective restlessness and objective motor signs (pacing, rocking, inability to sit still) 2, 4
• Reassess after 1-2 weeks of pharmacological treatment for akathisia
• Consider that chronic or tardive akathisia may develop if symptoms persist beyond 3 months, which can be more resistant to treatment 4

Long-Term Considerations for Bipolar II Management

Once akathisia is controlled, ensure the patient remains on appropriate mood stabilization for bipolar II disorder. First-line options include lithium, valproate, lamotrigine, or atypical antipsychotics (quetiapine, lurasidone, cariprazine, aripiprazole). 5, 6 The choice should balance efficacy for bipolar depression (the predominant phase in bipolar II) against side effect tolerability, particularly given this patient's akathisia vulnerability.